辽宁成大生物股份有限公司 章 程 二〇二五年八月 辽宁成大生物股份有限公 司 公司章程 目 录 辽宁成大生物股份有限公司 公司章程 和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司由辽宁成大生物技术有限公司整体变更设立；在辽宁省市场监督管理局注 册登记，取得营业执照，统一社会信用代码 91210000738792171J。 第三条 公司于 2021 年 9 月 14 日经上海证券交易所审核同意并完成在中国 证券监督管理委员会（以下简称"中国证监会"）的注册程序，首次向社会公众发 行人民币普通股 4,165 万股；于 2021 年 10 月 28 日在上海证券交易所上市。 第四条 公司注册名称： 中文全称：辽宁成大生物股份有限公司 英文全称：LIAONING CHENGDA BIOTECHNOLOGY CO., LTD. 第五条 公司住所：沈阳市浑南新区新放街 1 号；邮政编码：110179。 第六条 公司的注册资本为人民币 41,645 万元。 第七条 公司为永久存续的股份有限公司。 第八条 董事长为公司的法定代表人。董事长辞任的，视为同时辞去法定代 表人，公 ...

Core Insights - The South Korean health industry has achieved a record high in exports in the first half of the year, driven by significant growth in cosmetics and pharmaceuticals [1] Group 1: Export Performance - The total export value of the South Korean health industry reached $13.79 billion, marking a year-on-year increase of 13.2% [1] - Cosmetics exports amounted to $5.51 billion, with a year-on-year growth of 14.9%, while pharmaceuticals reached $5.38 billion, growing by 20.5% [1] - Both cosmetics and pharmaceuticals achieved their highest export values for the first half of the year [1] Group 2: Sector Contributions - Basic skincare products accounted for 74.6% of cosmetics exports, performing well in markets such as the United States, Hong Kong, and Poland [1] - The growth in pharmaceuticals was primarily driven by biopharmaceuticals and vaccine products [1] Group 3: Medical Devices - The medical device sector experienced a slight decline, with exports decreasing from $2.92 billion in the first half of last year to $2.91 billion this year, a drop of 0.6% [1]

8月5日，辉瑞(PFE)盘中上涨5.04%，截至22:43，报24.715美元/股，成交9.99亿美元，总市值1405.17亿 美元。 财务数据显示，截至2025年03月30日，辉瑞收入总额137.15亿美元，同比减少7.82%；归母净利润29.67 亿美元，同比减少4.75%。 本文源自：金融界 作者：行情君 8月5日，辉瑞(美东)盘前披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当地时 间，实际披露日期以公司公告为准）。 资料显示，辉瑞公司致力于运用科学以及他们的全球资源来改善每个生命阶段的健康状况。在药品的探 索、开发和生产过程中,他们多样化的全球保健产品包括生物药品、小分子药品和疫苗,以及许多世界驰 名的健康药物。每天,世界各地的辉瑞员工致力于推进健康,以及能够应对他们这个时代最为棘手的疾病 的预防和治疗方案。辉瑞还与世界各地的医疗卫生专业人士、政府和社区合作,支持世界各地的人们能 够获得更为可靠和可承付的医疗卫生服务。这与辉瑞作为一家世界领先的生物制药公司的责任是一致 的。160多年来,辉瑞一直努力为人们提供更好、更优质的服务。 大事提醒： ...

Group 1 - The core index of the CSI Hong Kong Stock Connect Biotechnology Theme Index closed at 1134.61 points, with a decline of 3.59% over the past month, an increase of 24.05% over the past three months, and a year-to-date increase of 20.15% [1] - The index consists of 50 listed companies involved in biopharmaceuticals, pharmaceuticals, and biotechnology services, reflecting the overall performance of biotechnology theme companies within the Hong Kong Stock Connect [1] - The index was established on December 28, 2018, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: BeiGene (15.69%), WuXi Biologics (11.81%), Innovent Biologics (10.68%), CanSino Biologics (8.36%), CSPC Pharmaceutical Group (6.36%), China Biologic Products (5.81%), Hansoh Pharmaceutical (3.68%), Zai Lab (3.48%), 3SBio (3.22%), and WuXi AppTec (2.82%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3 - In terms of industry composition, biopharmaceuticals account for 52.00%, chemical drugs for 25.67%, pharmaceutical and biotechnology services for 19.19%, and medical devices for 3.14% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year, with a sample adjustment ratio generally not exceeding 20% [2] - Special adjustments may occur under certain circumstances, such as delisting or significant corporate actions like mergers or acquisitions [2]